CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Dabigatran etexilate

Last Updated: March 18, 2013
Result type: Reports
Project Number: SF0320-000
Product Line: Common Drug Review

Generic Name: Dabigatran etexilate

Brand Name: Pradaxa

Manufacturer: Boehringer Ingelheim (Canada) Ltd

Indications: Atrial fibrillation prevention of stroke and systemic embolism

Submission Type: Request For Advice

Project Status: Complete

Date Recommendation Issued: July 18, 2013

Recommendation Type: List with clinical criteria and/or conditions